IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤中医
学科主题临床医学
Ren Shen Yangrong Tang for Fatigue in Cancer Survivors: A Phase I/II Open-Label Study
Xu, Yichen1; Chen, Yanzhi1; Li, Pingping1; Wang, Xin Shelley2
刊名JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
2015-05-01
DOI10.1089/acm.2014.0211
21期:5页:281-287
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Integrative & Complementary Medicine
资助者Key Program Foundation of Beijing Administration of TCM ; National Cancer Institute (NCI) of the National Institutes of Health ; MD Anderson Cancer Center ; Key Program Foundation of Beijing Administration of TCM ; National Cancer Institute (NCI) of the National Institutes of Health ; MD Anderson Cancer Center
研究领域[WOS]Integrative & Complementary Medicine
关键词[WOS]TRADITIONAL CHINESE MEDICINE ; DOUBLE-BLIND ; CLINICAL-TRIALS ; SYMPTOM BURDEN ; CHEMOTHERAPY ; PLACEBO
英文摘要

Objectives: This open-label, prospective, phase I/II trial was performed to establish the safety and efficacy of Traditional Chinese Medicine (TCM) herbal products for treating non-anemia-related fatigue in patients with cancer. Although this practice is widespread in China, it has not been confirmed in a prospective clinical study.

Design: Thirty-three patients who had completed cancer treatment, had stable disease and no anemia, and reported moderate to severe fatigue (rated >= 4 on a 0-10 scale) were enrolled in a TCM outpatient clinic. Patients took Ren Shen Yangrong Tang (RSYRT) decoction, a soup containing 12 TCM herbs, twice a day for 6 weeks. RSYRT aims to correct qi deficiency. Fatigue was assessed before and after RSYRT therapy, which all patients completed.

Results: No discomfort or toxicity was observed. Before the study, all patients had had fatigue for at least 4 months. Fatigue severity decreased significantly from before therapy to 6 weeks after therapy: from 7.06 to 3.30 on a 0-10 scale (p<0.001). Fatigue category (mild, moderate, severe) shifted significantly (p=0.024): Of 22 patients with severe fatigue (rated >= 7) before therapy, 11 had mild fatigue and 11 had moderate fatigue after TCM treatment. The time-to-fatigue-alleviation was 2-3 weeks.

Conclusion: RSYRT therapy was safe and was associated with fatigue improvement in nonanemic cancer survivors, consistent with historical TCM clinical practice experience. Because of a possible placebo effect in this open-label study, decoction RSYRT warrants further study in randomized clinical trials to confirm its effectiveness for managing moderate to severe fatigue.

语种英语
所属项目编号NCI P01 CA124787 ; NCI P30 CA016672
资助者Key Program Foundation of Beijing Administration of TCM ; National Cancer Institute (NCI) of the National Institutes of Health ; MD Anderson Cancer Center ; Key Program Foundation of Beijing Administration of TCM ; National Cancer Institute (NCI) of the National Institutes of Health ; MD Anderson Cancer Center
WOS记录号WOS:000354105100005
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64254
专题北京大学临床肿瘤学院_肿瘤中医
作者单位1.Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
2.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Tradit Chinese Med, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Xu, Yichen,Chen, Yanzhi,Li, Pingping,et al. Ren Shen Yangrong Tang for Fatigue in Cancer Survivors: A Phase I/II Open-Label Study[J]. JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE,2015,21(5):281-287.
APA Xu, Yichen,Chen, Yanzhi,Li, Pingping,&Wang, Xin Shelley.(2015).Ren Shen Yangrong Tang for Fatigue in Cancer Survivors: A Phase I/II Open-Label Study.JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE,21(5),281-287.
MLA Xu, Yichen,et al."Ren Shen Yangrong Tang for Fatigue in Cancer Survivors: A Phase I/II Open-Label Study".JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE 21.5(2015):281-287.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xu, Yichen]的文章
[Chen, Yanzhi]的文章
[Li, Pingping]的文章
百度学术
百度学术中相似的文章
[Xu, Yichen]的文章
[Chen, Yanzhi]的文章
[Li, Pingping]的文章
必应学术
必应学术中相似的文章
[Xu, Yichen]的文章
[Chen, Yanzhi]的文章
[Li, Pingping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。